In other studies, metformin, sulfonylurea, and sodium-glucose Cotransporter-2 Inhibitors decreased mortality risk, but insulin therapy and gliptins are linked with a high risk of severe outcome and mortality in COVID-19 [38]. Here, SLC5A2 is linked to COVID-19.